Esketamine Hydrochloride · ESKETAMINE HYDROCHLORIDE 28 mg/.2mL · Solution · Nasal · Janssen Pharmaceuticals, Inc.
NDC 50458-0028-02 · 2 BLISTER PACK in 1 KIT / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE · NDA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $426.30 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market · price up 8% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | I-959 | Jan 17, 2028 |
| patent | 11883526 | Feb 18, 2040 |
| patent | 11173134 | Sep 10, 2035 |
| patent | 10869844 | Sep 10, 2035 |
| patent | 11311500 | Sep 10, 2035 |
| patent | 11446260 | Mar 14, 2034 |
| patent | 8785500 | Mar 5, 2033 |
| patent | 9592207 | Mar 20, 2027 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc. | ESKETAMINE HYDROCHLORIDE 28 mg/.2mL | Aug 27, 2026 | Sep 3, 2026 |
| Janssen Pharmaceuticals Inc. | ESKETAMINE HYDROCHLORIDE 28 mg/.2mL | Jul 15, 2026 | Aug 26, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Spravato — NDC 50458-0028-02," retrieved September 3, 2026, https://drugdashboards.com/drug/50458002802.
Free to cite with attribution — see how the data is put together.